Search Results - "Angelosanto, N."

P501: CLI120‐001 PHASE1B DOSE ESCALATION STUDY OF RVU120 IN PATIENTS WITH AML OR HIGH RISK MDS SAFETY AND EFFICACY DATA UPDATE by Abboud, C., Jan Maciej, Z., Borthakur, G., Solomon, S., Howard, B., Bradley, T., Mouhayar, E., Angelosanto, N., Nogai, H., Glasmacher, A., Dudziak, R., Brzozka, K., Rzymski, T., Littlewood, P., Maranda, E.‐L.

Get full text

P450: PRECLINICAL AND CLINICAL SIGNS OF RVU120 EFFICACY, A SPECIFIC CDK8/19 INHIBITOR IN DNMT3A MUTATION POSITIVE AML AND HR‐MDS by Pakulska, U., Angelosanto, N., Mikula, M., Nogai, H., Dudziak, R., Abboud, C., Obacz, M., Goller, K., Cybulska, M., Mazan, M., Kozakowska, M., Rzymski, T.

Get full text

P520: PHASE 1/2 STUDY OF SEL24/MEN1703, A FIRST‐IN‐CLASS DUAL PIM/FLT3 KINASE INHIBITOR, IN PATIENTS WITH IDH1/2‐MUTATED ACUTE MYELOID LEUKEMIA: THE DIAMOND‐01 TRIAL by Martinelli, G., Santoro, A., Gambacorti‐Passerini, C., Vives Polo, S., Solomon, S. R., Mukherjee, S., Lech‐Maranda, E., Yair Levy, M., Wierzbowska, A., Calbacho‐Robles, M., Marconi, G., Benedetta Giannini, M., Cano, I., Torres Miñana, L., Acuña‐Cruz, E., Angelosanto, N., Galleu, A., Baldini, S., Blotta, S., Ravandi, F., Montesinos, P.

Get full text

Phase I/II trial of RVU120, a CDK8/CDK19 inhibitor in patients with relapsed/refractory metastatic or advanced solid tumors by Dziadziuszko, R., Garralda Cabanas, E., Rojas, K., Chelstowska, M., Blaszkowska, M., Dudziak, R., Rzymski, T., Angelosanto, N., Littlewood, P., Nogai, H., Boni, V., Lugowska, I.

Get full text